PT  - JOURNAL ARTICLE
AU  - Wang, Gang
AU  - Wang, Guixia
TI  - Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes
AID  - 10.15537/smj.2025.46.3.20240920
DP  - 2025 Mar 01
TA  - Saudi Medical Journal
PG  - 213--225
VI  - 46
IP  - 3
4099  - http://smj.org.sa/content/46/3/213.short
4100  - http://smj.org.sa/content/46/3/213.full
SO  - Saudi Med J2025 Mar 01; 46
AB  - Hyperuricemia and type 2 diabetes mellitus (T2DM) are interconnected, in that each disorder increases risk for the other. Some antidiabetic drugs may decrease the level of serum uric acid (SUA). This narrative review describes the effects of multiple antidiabetic drugs on the SUA level and their possible mechanisms of action in patients with T2DM. The results showed that sodium glucose contransporter-2 inhibitors (SGLT2is), thiazolidinediones, metformin, and linagliptin decreased the SUA; insulin, sitagliptin, and alogliptin increased the SUA; and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sulfonylureas, and alpha-glucosidase inhibitors had little effect on the SUA. Sodium glucose contransporter-2 inhibitors appeared to have the greatest effect on lowering SUA, possibly because they reduce pentose phosphate pathway metabolism and increase the renal excretion of urate by altering renal tubular uric acid transporters. Among all antidiabetic drugs currently used, SGTL2is appeared to be the most promising therapeutic option for T2DM patients with hyperuricemia.